Lisanti Capital Growth’s Amedisys AMED Stock Holding History

Lisanti Capital Growth’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,770	Closed	-$2.28M	–	127
2020 Q4	$2.28M	Sell	7,770 -9,442	-55%	-$2.42M	0.32%	97
2020 Q3	$4.07M	Sell	17,212 -6,123	-26%	-$1.39M	0.75%	61
2020 Q2	$4.63M	Buy	23,335 +1,780	+8%	+$332K	0.94%	46
2020 Q1	$3.96M	Sell	21,555 -27,442	-56%	-$4.88M	1.31%	26
2019 Q4	$8.18M	Buy	+48,997	New	+$7.29M	2.17%	2
2019 Q1	–	Sell	-38,810	Closed	-$4.54M	–	114
2018 Q4	$4.54M	Buy	38,810 +7,740	+25%	+$912K	1.84%	13
2018 Q3	$3.88M	Buy	31,070 +3,800	+14%	+$420K	1.35%	28
2018 Q2	$2.33M	Buy	+27,270	New	+$2M	0.89%	52
2016 Q3	–	Sell	-12,745	Closed	-$643K	–	96
2016 Q2	$643K	Sell	12,745 -1,115	-8%	-$56.3K	0.97%	51
2016 Q1	$670K	Buy	+13,860	New	+$535K	0.79%	60
2015 Q4	–	Sell	-14,160	Closed	-$538K	–	90
2015 Q3	$538K	Buy	+14,160	New	+$597K	0.48%	79

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Lisanti Capital Growth's AMED Position: Q1 2021 in Review

Lisanti Capital Growth sold out of Amedisys (AMED) in Q1 2021, closing a stake of 7,770 shares — an estimated $2.28M sold.

Lisanti Capital Growth first reported a position in AMED in Q3 2015 and held it in 11 quarters. The position peaked at $8.18M in Q4 2019. 389 funds tracked by Wall St. Rank hold AMED as of Q1 2021.

Lisanti Capital Growth reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
Lisanti Capital Growth sold 7,770 Amedisys shares in Q1 2021, an estimated $2.28M.
Lisanti Capital Growth first reported a position in Amedisys in Q3 2015 and held it in 11 quarters.
Lisanti Capital Growth's Amedisys position peaked at $8.18M in Q4 2019.
389 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.

Based on Lisanti Capital Growth's 13F filing for Q1 2021, filed 12 May 2021.